Biotechnology

ImmunityBio

ImmunityBio Presents Data Showing NAI+BCG Outperforms nadofaragene and TAR-200 in Efficacy and Safety

ImmunityBio Presents ANKTIVA Plus BCG Outperforms Competitors with Better Efficacy and Safety at 2026 AUA

ImmunityBio Secures Exclusive US Rights to Tokyo-172 BCG Strain from Japan's BCG Lab

ImmunityBio Secures 5 U.S. Patents for ANKTIVA Plus BCG Combination Through 2035

ImmunityBio Signs Exclusive US Deal with Japan BCG Lab to Boost Supply

ImmunityBio released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 44.21 M (forecast USD 43.94 M), actual EPS USD -0.6162 (forecast USD -0.07)

ImmunityBio to Report Q1 2026 Earnings

ImmunityBio Announces Pancreatic Cancer Clinical Trial

ImmunityBio Launches ANKTIVA in Saudi Arabia

ImmunityBio Reports Q1 2026 Revenue Exceeding Expectations

ImmunityBio Secures $100 Million in Funding for Anktiva Sales Expansion

IBRX Option Market Trading Conditions

ImmunityBio's ANKTIVA Plus BCG Recommended in 2026 NCCN Bladder Cancer Guidelines

ImmunityBio Completes NK Cell Manufacturing Projects, Shares Rise

ImmunityBio Completes Phase 1 Clinical Trial of M-ceNK Cells and ANKTIVA Combination Therapy

ImmunityBio Releases Investor Presentation on Immune Therapy Platform

ImmunityBio Beats Earnings Expectations Despite Share Price Decline

ImmunityBio Reports Superior Bladder Cancer Trial Response Rate, Shares Rise

ImmunityBio released FY2025 earnings on February 23, 2026 (EST), with actual revenue of USD 113.29 M (forecast USD 112.82 M) and actual EPS of USD -0.382 (forecast USD -0.406)

ImmunityBio released FY2025 Q4 earnings on February 23 (EST), actual revenue USD 38.29M (forecast USD 37.78M), actual EPS USD -0.0625 (forecast USD -0.094)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

IBRX

LABU

SBIO

Investors who suffered losses in ImmunityBio, Inc. (NASDAQ: IBRX) have the opportunity to lead a securities fraud class action lawsuit. The complaint alleges that the company misled investors about Anktiva's capabilities between January 19, 2026, and March 24, 2026. Interested parties must act before May 26, 2026, to participate.

prnewswire

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

15:47 ETImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBBQ

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | IBRX Stock News

StockTitan

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | IBRX Stock News

ImmunityBio presented data at AUA 2026 showing that NAI+BCG treatment resulted in significantly higher complete response rates and longer durations compared to nadofaragene and TAR-200 for BCG-unresponsive non-muscle invasive bladder cancer. NAI+BCG patients had a 69.7% response rate and a median duration of 22.1 months, while nadofaragene had 53.4% and 9.7 months. Additionally, NAI+BCG showed fewer treatment-related adverse events compared to TAR-200, indicating its potential as a preferred therapy.

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 | IBRX Stock News

ImmunityBio has secured exclusive U.S. rights to the Tokyo-172 BCG strain through a supply agreement with Japan BCG Laboratory. The agreement allows ImmunityBio to develop, conduct clinical trials, and manage regulatory approvals for 10 years post-FDA approval, with no upfront payments required. After approval, ImmunityBio must purchase at least two batches annually. The deal also includes rights for certain ex-U.S. territories.

TradingView

ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory

LABD

Rosen Law Firm is reminding investors of ImmunityBio, Inc. (NASDAQ: IBRX) about the May 26, 2026 deadline to lead a securities fraud class action lawsuit. Investors who purchased shares between January 19, 2026, and March 24, 2026, may be eligible for compensation. The lawsuit alleges misleading statements regarding the company's operations. Interested parties can contact the firm for more information.

Direxion S&P Biotech Bear 3X

14:56 ETImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

ImmunityBio(IBRX.US)

15:47 ETImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | IBRX Stock News

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 | IBRX Stock News

ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory

14:56 ETImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm